Valneva SE (VALN) Depreciation & Amortization (CF) (2022 - 2026)
Valneva SE's (VALN) quarterly Depreciation & Amortization (CF) came in at $4.9 million in Q1 2026, up 11.3% year-on-year from $4.4 million in Q1 2025, and down 1.76% quarter-over-quarter from $5.0 million in Q4 2025.
Valneva SE (VALN) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Valneva SE has disclosed Depreciation & Amortization (CF) across 5 years of filings, most recently posting $4.9 million for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $4.9 million, up 11.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.6 million (up 18.53% YoY), and the FY2025 annual result was $19.7 million, up 25.23% from the prior year.
- Depreciation & Amortization (CF) came in at $4.9 million for Q1 2026 at Valneva SE, down from $5.0 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.7 billion in Q3 2022 to a low of -$10.8 billion in Q4 2022.
- The 5-year median for Depreciation & Amortization (CF) is $4.1 million (2024), against an average of -$4.5 million.
- Peak annual rise in Depreciation & Amortization (CF) reached 100.03% in 2023, while the deepest fall reached 99.97% in 2023.
- Valneva SE's Depreciation & Amortization (CF) stood at -$10.8 billion in 2022, then jumped by 100.03% to $3.7 million in 2023, then rose by 16.84% to $4.3 million in 2024, then climbed by 17.1% to $5.0 million in 2025, then dropped by 1.76% to $4.9 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $4.9 million (Q1 2026), $5.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 4.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.92 Mn |
| Mar 31, 2026 | 4.92 Mn |
| Dec 31, 2025 | 5.01 Mn |
| Dec 31, 2025 | 5.01 Mn |
| Sep 30, 2025 | 4.91 Mn |
| Sep 30, 2025 | 4.91 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.42 Mn |
| Mar 31, 2025 | 4.42 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 3.66 Mn |
| Dec 31, 2023 | 3.66 Mn |